[开放获取]    斑块状银屑病生物制剂长程治疗管理专家共识（2026版）

doi:10.35541/cjd.20250460

中华皮肤科杂志 ›› 2026, e20250460.doi: 10.35541/cjd.20250460

[开放获取] 斑块状银屑病生物制剂长程治疗管理专家共识（2026版）

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤病学分会

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤病学分会

收稿日期:2025-08-25 修回日期:2026-05-29 发布日期:2026-06-24
通讯作者: 晋红中；王刚 E-mail:jinhongzhong@263.net; xjwgang@fmmu.edu.cn
基金资助:
国家重点研发计划（2022YFC3601800）；中央高水平医院临床科研业务费（2022-PUMCH-B-092）；协和人才培育支持计划D类项目（UHB11983）；北京市临床重点专科项目；国家临床重点专科建设项目

Expert consensus on the long-term management of plaque psoriasis with biologic agents （2026 edition）

China Dermatologist Association; Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; Dermatology Branch of China Alliance for Rare Diseases

China Dermatologist Association; Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; Dermatology Branch of China Alliance for Rare Diseases

Received:2025-08-25 Revised:2026-05-29 Published:2026-06-24
Contact: Jin Hongzhong; Wang Gang E-mail:jinhongzhong@263.net; xjwgang@fmmu.edu.cn
Supported by:
National Key R&D Program of China （2022YFC3601800）; National High Level Hospital Clinical Research Funding （2022-PUMCH-B-092）; Peking Union Medical College Hospital Talent Cultivation Program Category D （UHB11983）; Beijing Key Clinical Specialty Construction Project; National Key Clinical Specialty Project of China

摘要/Abstract

摘要： 【摘要】银屑病是一种免疫介导的慢性、系统性、炎症性疾病，反复发作，长程治疗管理对控制病情、延缓疾病进展及预防共病发生具有重要意义。近年来，生物制剂已逐渐成为中重度斑块状银屑病长期治疗的重要系统治疗药物，并显示出良好的疗效。本共识基于近年来斑块状银屑病生物制剂长程治疗研究进展及国内外银屑病生物制剂治疗指南/共识，结合专家自身临床经验，针对斑块状银屑病生物制剂长程（48周至10年）治疗的疗效及维持方案、安全性、特殊人群管理（如老年人群）、共病管理等4大类共15个临床问题，形成23条推荐意见，为临床规范应用生物制剂长期控制斑块状银屑病提供参考，优化治疗策略、改善治疗结局。

关键词: 银屑病, 生物制剂, 病例管理, 老年人, 共病, 斑块状银屑病, 专家共识

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic, systemic, inflammatory disease characterized by recurrent episodes. Long-term disease management is essential for disease control, delaying disease progression, and preventing the development of comorbidities. In recent years, biologic agents have gradually become an important systemic treatment option for the long-term management of moderate-to-severe plaque psoriasis and have demonstrated favorable efficacy. Based on recent advances in research on the long-term use of biologic agents for plaque psoriasis, as well as national and international guidelines and consensus statements on biologic therapy for psoriasis, and incorporating the clinical experience of experts, this consensus addresses 15 clinical questions in four major domains, including the efficacy and maintenance strategies of long-term biologic therapy （48 weeks to 10 years）, safety, management of special populations （e.g., older adults）, and comorbidity management. A total of 23 recommendations were developed to provide guidance for the standardized long-term use of biologic agents in plaque psoriasis, with the aim of optimizing treatment strategies and improving clinical outcomes.

Key words: Psoriasis, Biologic agents, Case management, Aged, Comorbidity, Plaque psoriasis, Expert consensus

中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤病学分会 . [开放获取] 斑块状银屑病生物制剂长程治疗管理专家共识（2026版）[J]. 中华皮肤科杂志, 2026,e20250460. doi:10.35541/cjd.20250460

China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Dermatology Branch of China Alliance for Rare Diseases. Expert consensus on the long-term management of plaque psoriasis with biologic agents （2026 edition）[J]. Chinese Journal of Dermatology,2026,e20250460. doi:10.35541/cjd.20250460

参考文献 155

［1］	Alcusky M, Lee S, Lau G, et al. Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis［J］. Dermatol Ther （Heidelb）, 2017,7（4）:463⁃483. DOI: 10.1007/s13555⁃017⁃0205⁃2.
［2］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南（2024版）［J］. 中华皮肤科杂志, 2024,57（11）:976⁃997. DOI: 10.35541/cjd.20240294.
［3］	Kristian R, Christopher G, Jonathan B, et al. Recommendations for the long⁃term treatment of psoriasis with infliximab: a dermatology expert group consensus［J］. Dermatology, 2008,217（3）:268⁃275. DOI: 10.1159/000149970.
［4］	Puig L, Carrascosa J M, Carretero G, et al. Spanish evidence⁃based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology［J］. Actas Dermosifiliogr, 2013,104（8）:694⁃709. DOI: 10.1016/j.adengl.2013.04.013.
［5］	Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009［J］. Br J Dermatol, 2009,161（5）:987⁃1019. DOI: 10.1111/j.1365⁃2133.2009.09505.x.
［6］	Kristian R, Armstrong April W, Langley Richard G, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. DOI: 10.1016/S0140⁃6736（19）31773⁃8.
［7］	Gordon KB, Warren RB, Gottlieb AB, et al. Long⁃term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3⁃year results from two randomized phaseⅢ trials （CIMPASI⁃1 and CIMPASI⁃2）［J］. Br J Dermatol, 2021,184（4）:652⁃662. DOI: 10.1111/bjd.19393.
［8］	Onsun N, Güneş B, Yabacı A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID⁃19 pandemic: the real⁃world experience of a single center［J］. Dermatol Ther, 2021,34（1）:e14623. DOI: 10. 1111/dth.14623.
［9］	Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy （SORT）: a patient⁃centered approach to grading evidence in the medical literature［J］. J Am Board Fam Pract, 2004,17（1）:59⁃67. DOI: 10.3122/jabfm.17.1.59.
［10］	Guyatt Gordon H, Oxman Andrew D, Vist Gunn E, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations［J］. BMJ, 2008,336（7650）:924⁃926. DOI: 10.1136/bmj.39489.470347.AD.
［11］	Tyring S, Gordon KB, Poulin Y, et al. Long⁃term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis［J］. Arch Dermatol, 2007,143（6）:719⁃726. DOI: 10. 1001/archderm.143.6.719.
［12］	Raudonis T, Gliebute A, Grigaityte AG, et al. A six⁃year analysis of biological therapy for severe psoriasis in a lithuanian reference centre of dermatovenereology［J］. Medicina （Kaunas）, 2020,56（6）:275. DOI: 10.3390/medicina56060275.
［13］	Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2007,56（1）:31. DOI: 10.1016/j.jaad.2006.07.017.
［14］	Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL［J］. J Am Acad Dermatol, 2012,66（2）:241⁃251. DOI: 10.1016/j.jaad.2010.12.005.
［15］	Onsun N, Güneş B, Kaya G, et al. Comparison of survival and retention rates between infliximab and adalimumab for psoriasis: 10⁃year experience at a single tertiary center［J］. Dermatology, 2023,239（3）:355⁃361. DOI: 10.1159/000529964.
［16］	Romero⁃Jimenez RM, Escudero⁃Vilaplana V, Rodriguez OB, et al. Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol［J］. J Dermatolog Treat, 2016,27（3）:198⁃202. DOI: 10.3109/09546634. 2015.1088127.
［17］	Taniguchi T, Noda S, Takahashi N, et al. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment［J］. J Eur Acad Dermatol Venereol, 2013,27（11）:1444⁃1447. DOI: 10.1111/j.1468⁃3083.2012.04610.x.
［18］	Owczarczyk⁃Saczonek A, Owczarek W, Osmola⁃Mańkowska A, et al. Secondary failure of TNF⁃α inhibitors in clinical practice［J］. Dermatol Ther, 2019,32（1）:e12760. DOI: 10.1111/dth. 12760.
［19］	Bissonnette R, Bolduc C, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept［J］. J Am Acad Dermatol, 2010,63（2）:228⁃234. DOI: 10.1016/j.jaad.2009.08.040.
［20］	Ayala F, Lambert J. Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate⁃to⁃severe psoriasis: a multicenter, open⁃label trial （TANGO）［J］. J Dermatolog Treat, 2015,26（4）:304⁃311. DOI: 10.3109/09546634. 2014.952611.
［21］	Tsai Y, Tsai T. Switching biologics in psoriasis ⁃ practical guidance and evidence to support［J］. Expert Rev Clin Pharmacol, 2020,13（5）:493⁃503. DOI: 10.1080/17512433.2020.1767590.
［22］	Reich K, Papp K, Blauvelt A, et al. Tildrakizumab, a selective anti⁃IL⁃23 monoclonal antibody, is effective in subjects with chronic plaque psoriasis who do not adequately respond to etanercept［J］. J Am Acad Dermatol, 2017, 76（6）: AB259. DOI: 10.1016/j.jaad.2017.04.1008.
［23］	Matteo M, Luca P, Angelo R, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti⁃IL17: a 52⁃week real⁃life study［J］. J Dermatolog Treat, 2022,33（5）:2560⁃2564. DOI: 10.1080/09546634.2022.2036674.
［24］	Torii H, Nakano M, Yano T, et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study［J］. J Dermatol, 2017,44（5）:552⁃559. DOI: 10.1111/1346⁃8138.13698.
［25］	Yamauchi PS, Bissonnette R, Teixeira HD, et al. Systematic review of efficacy of anti⁃tumor necrosis factor （TNF） therapy in patients with psoriasis previously treated with a different anti⁃TNF agent［J］. J Am Acad Dermatol, 2016,75（3）:612⁃618. DOI: 10.1016/j.jaad.2016.02.1221.
［26］	Takamura S, Sugai S, Taguchi R, et al. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue［J］. J Dermatol, 2020,47（3）:290⁃294. DOI: 10.1111/1346⁃8138.15193.
［27］	van den Reek JMPA, van Lümig PPM, Kievit W, et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice［J］. J Dermatolog Treat, 2013,24（5）:361⁃368. DOI: 10.3109/09546634.2012.751483.
［28］	Mastorino L, Susca S, Cariti C, et al. Efficacy of anti⁃IL⁃23 and anti⁃IL⁃17 after adalimumab failure in psoriatic patients［J］. J Eur Acad Dermatol Venereol, 2023,37（9）:1848⁃1853. DOI: 10. 1111/jdv.19135.
［29］	Reich K, Gordon KB, Strober BE, et al. Five⁃year maintenance of clinical response and health⁃related quality of life improvements in patients with moderate⁃to⁃severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2［J］. Br J Dermatol, 2021,185（6）:1146⁃1159. DOI: 10.1111/bjd.20568.
［30］	Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 52⁃week results from a randomised, double⁃blind, placebo⁃controlled trial （PHOENIX 2）［J］. Lancet, 2008,371（9625）:1675⁃1684. DOI: 10.1016/S0140⁃6736（08）60726⁃6.
［31］	Langley RG, Lebwohl M, Krueger GG, et al. Long⁃term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate⁃to⁃severe psoriasis: results from the PHOENIX 2 study through 5 years of follow⁃up［J］. Br J Dermatol, 2015,172（5）:1371⁃1383. DOI: 10.1111/bjd.13469.
［32］	Kimball AB, Papp KA, Wasfi Y, et al. Long⁃term efficacy of ustekinumab in patients with moderate⁃to⁃severe psoriasis treated for up to 5 years in the PHOENIX 1 study［J］. J Eur Acad Dermatol Venereol, 2013,27（12）:1535⁃1545. DOI: 10. 1111/jdv.12046.
［33］	Blauvelt A, Ferris LK, Yamauchi PS, et al. Extension of ustekinumab maintenance dosing interval in moderate⁃to⁃severe psoriasis: results of a phaseⅢb, randomized, double⁃blinded, active⁃controlled, multicentre study （PSTELLAR）［J］. Br J Dermatol, 2017,177（6）:1552⁃1561. DOI: 10.1111/bjd.15722.
［34］	Langley RG, Tsai T, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double⁃blind, phaseⅢ NAVIGATE trial［J］. Br J Dermatol, 2018,178（1）:114⁃123. DOI: 10.1111/bjd.15750.
［35］	Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment （SCULPTURE Extension Study）［J］. J Eur Acad Dermatol Venereol, 2018,32（9）:1507⁃1514. DOI: 10. 1111/jdv.14878.
［36］	Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36. DOI: 10.1016/j.jaad.2015. 04.011.
［37］	Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every⁃2⁃week dosing of ixekizumab over 52 weeks in patients with moderate⁃to⁃severe plaque psoriasis in a randomized phaseⅢ trial （IXORA⁃P）［J］. Br J Dermatol, 2018,178（6）:1315⁃1323. DOI: 10.1111/bjd.16426.
［38］	Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long⁃term efficacy and safety of ixekizumab: a 5⁃year analysis of the UNCOVER⁃3 randomized controlled trial［J］. J Am Acad Dermatol, 2021,85（2）:360⁃368. DOI: 10.1016/j.jaad.2020.11.022.
［39］	Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate⁃to⁃severe plaque psoriasis: results from the randomized, open⁃label OPTIMISE study［J］. Br J Dermatol, 2020,182（2）:304⁃315. DOI: 10.1111/bjd.18143.
［40］	Imafuku S, Torisu⁃Itakura H, Nishikawa A, et al. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate⁃to⁃severe plaque psoriasis: subgroup analysis of a placebo⁃controlled, phase 3 study （UNCOVER⁃1）［J］. J Dermatol, 2017,44（11）:1285⁃1290. DOI: 10.1111/1346⁃8138. 13927.
［41］	Phung M, Ighani A, Georgakopoulos JR, et al. Off⁃label high⁃dose secukinumab for the treatment of moderate⁃to⁃severe psoriasis［J］. J Cutan Med Surg, 2019,23（4）:391⁃393. DOI: 10. 1177/1203475419843118.
［42］	Georgakopoulos JR, Phung M, Ighani A, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies［J］. J Am Acad Dermatol, 2018,79（1）:155⁃157. DOI: 10.1016/j.jaad.2018.01.003.
［43］	Boswell ND, Singla S, Gordon KB. Sequencing of targeted therapy in psoriasis: does it matter?［J］. Am J Clin Dermatol, 2024,25（5）:795⁃810. DOI: 10.1007/s40257⁃024⁃00874⁃z.
［44］	Chiricozzi A, Conti A, Burlando M, et al. Switching from secukinumab to ustekinumab in psoriasis patients: results from a multicenter experience［J］. Dermatology, 2019,235（3）:213⁃218. DOI: 10.1159/000497274.
［45］	Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy （rescue therapy）: data from a multicenter real⁃life study in a cohort of Italian psoriatic patients that avoided secukinumab switching［J］. Pharmaceuticals （Basel）, 2022,15（1）:95. DOI: 10.3390/ph15010095.
［46］	Griffiths CEM, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate⁃to⁃severe psoriasis: results from VOYAGE 1［J］. J Dermatolog Treat, 2022,33（2）:848⁃856. DOI: 10.1080/09546634.2020.1782817.
［47］	Thaci D, Piaserico S, Warren RB, et al. Five⁃year efficacy and safety of tildrakizumab in patients with moderate⁃to⁃severe psoriasis who respond at week 28: pooled analyses of two randomized phaseⅢ clinical trials （reSURFACE 1 and reSURFACE 2）［J］. Br J Dermatol, 2021,185（2）:323⁃334. DOI: 10.1111/bjd.19866.
［48］	Reich K, Warren RB, Iversen L, et al. Long⁃term efficacy and safety of tildrakizumab for moderate⁃to⁃severe psoriasis: pooled analyses of two randomized phaseⅢ clinical trials （reSURFACE 1 and reSURFACE 2） through 148 weeks［J］. Br J Dermatol, 2020,182（3）:605⁃617. DOI: 10.1111/bjd.18232.
［49］	Kilian E, Khusru A, Andreas P, et al. Noninferiority of 16⁃week vs 8⁃week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial［J］. JAMA Dermatol, 2024,160（9）:953⁃963. DOI: 10.1001/jamadermatol.2024.2463.
［50］	Mufti A, Maliyar K, Walton L, et al. Guselkumab dosing interval optimization in adult patients with psoriasis: a retrospective, multicenter case series［J］. J Am Acad Dermatol, 2020,83（6）:1813⁃1814. DOI: 10.1016/j.jaad.2020.04.025.
［51］	van der Schoot LS, Janssen JJ, Bastiaens MT, et al. Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice［J］. J Dermatolog Treat, 2023,34（1）:2186728. DOI: 10.1080/09546634.2023.2186728.
［52］	van Muijen M E, van der Schoot L S, van den Reek J M P A, et al. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide［J］. Arch Dermatol Res, 2022,314（7）:687⁃695. DOI: 10.1007/s00403⁃021⁃02273⁃4.
［53］	van Riel CAM, Michielsens CAJ, van Muijen ME, et al. Dose reduction of biologics in patients with plaque psoriasis: a review［J］. Front Pharmacol, 2024,15:1369805. DOI: 10.3389/fphar. 2024.1369805.
［54］	van der Schoot LS, Baerveldt EM, van Enst WA, et al. National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure［J］. J Dermatolog Treat, 2022:2154570. DOI: 10.1080/09546634.2022.2154570.
［55］	van der Schoot Lara S, van den Reek Juul M P A, Lynda G, et al. Dose reduction of the new generation biologics （IL⁃17 and IL⁃23 inhibitors） in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non⁃inferiority study⁃the BeNeBio study［J］. Trials, 2021,22（1）:707. DOI: 10.1186/s13063⁃021⁃05681⁃z.
［56］	Kojanova M, Cetkovska P, Strosova D, et al. Real⁃world evidence from more than 1000 patients treated with adalimumab for moderate⁃to⁃severe psoriasis in the Czech Republic［J］. Dermatol Ther （Heidelb）, 2021,11（2）:543⁃553. DOI: 10.1007/s13555⁃021⁃00499⁃8.
［57］	Kim BS, Jo SJ, Youn S, et al. Five⁃year maintenance of clinical response and consistent safety profile for guselkumab in asian patients with psoriasis from VOYAGE 1 and VOYAGE 2［J］. Dermatol Ther （Heidelb）, 2023,13（11）:2721⁃2737. DOI: 10. 1007/s13555⁃023⁃01026⁃7.
［58］	虞英媛, 李影, 余增洋, 等. 英夫利西单抗治疗重度斑块状银屑病的疗效和安全性及其对PD⁃1、PD⁃L1表达的影响［J］. 中华皮肤科杂志, 2021,54（7）:590⁃596. DOI: 10.35541/cjd.2020 1071.
［59］	《司库奇尤单抗治疗银屑病专家共识》编写组. 司库奇尤单抗治疗银屑病专家共识［J］. 中华皮肤科杂志, 2024,57（12）:1079⁃1090. DOI: 10.35541/cjd.20240226.
［60］	Chicharro P, Rodríguez⁃Jiménez P, De la Fuente H, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti⁃IL⁃17 therapy［J］. J Allergy Clin Immunol Pract, 2020,8（10）:3619⁃3621. DOI: 10.1016/j.jaip.2020.06.064.
［61］	Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti⁃interleukin 17 treatment of psoriasis: an emerging condition［J］. Br J Dermatol, 2019,181（3）:604⁃606. DOI: 10.1111/bjd.17779.
［62］	Al⁃Janabi A, Alabas OA, Yiu ZZN, et al. Risk of paradoxical eczema in patients receiving biologics for psoriasis［J］. JAMA Dermatol, 2024,160（1）:71⁃79. DOI: 10.1001/jamadermatol. 2023.4846.
［63］	Brunner PM, Conrad C, Vender R, et al. Integrated safety analysis of treatment⁃emergent eczematous reactions in patients with moderate⁃to⁃severe psoriasis treated with ixekizumab, etanercept and ustekinumab［J］. Br J Dermatol, 2021,185（4）:865⁃867. DOI: 10.1111/bjd.20527.
［64］	Li Q, Li X, Li W, et al. Development of IL⁃17A inhibitor⁃induced atopic dermatitis⁃like rash in psoriasis patients: Insights into immune shift［J］. Exp Dermatol, 2024,33（1）:e14958. DOI: 10.1111/exd.14958.
［65］	Sanz⁃Bueno J, Vanaclocha F, García⁃Doval I, et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database［J］. Actas Dermosifiliogr, 2015,106（6）:477⁃482. DOI: 10.1016/j.ad.2015.01.010.
［66］	Kłujszo EH, Zarębska⁃Michaluk D, Kręcisz B, et al. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection［J］. Dermatol Ther, 2022,35（3）:e15274. DOI: 10.1111/dth.15274.
［67］	Megna M, Patruno C, Bongiorno MR, et al. Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real⁃world setting of hepatitis B or hepatitis C infection［J］. Clin Drug Investig, 2022,42（6）:525⁃531. DOI: 10.1007/s40261⁃022⁃01163⁃5.
［68］	Mortato E, Talamonti M, Marcelli L, et al. A long⁃term real⁃world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study［J］. Clin Exp Dermatol, 2025,50（9）:1786⁃1794. DOI: 10.1093/ced/llaf172.
［69］	Kridin K, Zirpel H, Mruwat N, et al. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors ⁃ a population⁃based study［J］. J Eur Acad Dermatol Venereol, 2023,37（11）:2319⁃2326. DOI: 10.1111/jdv.19328.
［70］	Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1853⁃1859. DOI: 10.1111/jdv.14146.
［71］	Yu⁃Huei H, Ju⁃Shao Y, Shu⁃Hao L, et al. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: a multicenter prospective cohort study［J］. J Am Acad Dermatol, 2024,90（5）:1083⁃1086. DOI: 10.1016/j.jaad.2024.01.039.
［72］	Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis［J］. Br J Dermatol, 2019,181（1）:202⁃203. DOI: 10.1111/bjd.17604.
［73］	Conti A, Piaserico S, Gisondi P, et al. Management of long⁃term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting［J］. Dermatol Ther, 2017,30（5）:12503. DOI: 10.1111/dth.12503.
［74］	Yuan L, Li Y, Lin J, et al. Safety of biologics for psoriatic patients with latent tuberculosis［J］. Clin Cosmet Investig Dermatol, 2023,16:2333⁃2336. DOI: 10.2147/CCID.S426253.
［75］	Hsiao C, Chiu H, Wang T, et al. Serial QuantiFERON⁃TB gold testing in patients with psoriasis treated with ustekinumab［J］. PLoS One, 2017,12（9）:e0184178. DOI: 10.1371/journal.pone. 0184178.
［76］	Kammüller M, Tsai T, Griffiths CE, et al. Inhibition of IL⁃17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections［J］. Clin Transl Immunology, 2017,6（8）:e152. DOI: 10.1038/cti.2017.34.
［77］	He C, Wu C, Zhang L, et al. Interleukin⁃17A inhibitors in patients with psoriasis and tuberculosis infection: a 2⁃year prospective study on safety without preventive treatment［J］. Dermatol Ther （Heidelb）, 2024,14（4）:893⁃906. DOI: 10.1007/s13555⁃024⁃01130⁃2.
［78］	Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis［J］. J Am Acad Dermatol, 2020,83（5）:1436⁃1439. DOI: 10.1016/j.jaad.2020. 06.012.
［79］	Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry［J］. J Am Acad Dermatol, 2017,77（5）:845⁃854. DOI: 10.1016/j.jaad.2017.07.013.
［80］	Chou YJ, Wu CY, Pan TY, et al. Risk of malignancy in patients with psoriasis receiving systemic medications: a nested case⁃control study［J］. Dermatol Ther, 2022,35（11）:e15804. DOI: 10.1111/dth.15804.
［81］	van Lümig PPM, Menting SP, van den Reek JMPA, et al. An increased risk of non⁃melanoma skin cancer during TNF⁃inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease⁃related factors［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:752⁃760. DOI: 10. 1111/jdv.12675.
［82］	Chiesa Fuxench Zelma C, Shin Daniel B, Alexis OB, et al. The risk of cancer in patients with psoriasis: a population⁃based cohort study in the health improvement network［J］. JAMA Dermatol, 2016,152（3）:282⁃290. DOI: 10.1001/jamadermatol. 2015.4847.
［83］	van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long⁃term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:83⁃98. DOI: 10.1016/j.jaad.2016.03.024.
［84］	Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. DOI: 10.1111/jdv.15653.
［85］	Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. DOI: 10.1016/j.jaad.2019.11.040.
［86］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. DOI: 10.1016/S0140⁃6736（17）31189⁃3.
［87］	Lernia VD, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi⁃center, retrospective real⁃life study up to 52 weeks observation［J］. Dermatol Ther, 2019,32（6）:e13091. DOI: 10.1111/dth.13091.
［88］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. DOI: 10.1111/bjd.19018.
［89］	Landells I, Marano C, Hsu M, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. DOI: 10.1016/j.jaad.2015.07.002.
［90］	Ladha MA, Rankin BD, Adly M, et al. Real⁃world experience with ustekinumab for the treatment of plaque psoriasis in pediatric patients: a retrospective, single⁃center chart review［J］. J Am Acad Dermatol, 2022,87（5）:1143⁃1145. DOI: 10.1016/j.jaad.2022.02.022.
［91］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. DOI: 10.1111/jdv.17002.
［92］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. DOI: 10.35541/cjd.20220652.
［93］	Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2⁃year period［J］. Clin Exp Dermatol, 2016,41（5）:564⁃566. DOI: 10.1111/ced.12850.
［94］	Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase iii studies［J］. Drugs Aging, 2018,35（2）:135⁃144. DOI: 10.1007/s40266⁃018⁃0520⁃z.
［95］	Megna M, Camela E, Cinelli E, et al. Real⁃life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2⁃year period［J］. Clin Exp Dermatol, 2020,45（7）:848⁃852. DOI: 10.1111/ced.14258.
［96］	Megna M, Cinelli E, Balato A, et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1⁃year period［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:e152⁃e153. DOI: 10.1111/jdv.16063.
［97］	Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti⁃interleukin⁃23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real⁃world practice［J］. Clin Exp Dermatol, 2022,47（3）:561⁃567. DOI: 10.1111/ced.14979.
［98］	金兰, 邱云, 王唯嘉, 等. 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析［J］. 中华皮肤科杂志, 2025,58（1）:47⁃52. DOI: 10.35541/cjd.20240351.
［99］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. DOI: 10.35541/cjd.20220839.
［100］	Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti⁃tumor necrosis factor⁃alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long⁃term study［J］. Dermatology, 2012,225（4）:312⁃319. DOI: 10.1159/000345623.
［101］	Andrea C, Athanasios P, Annunziata D, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65［J］. Expert Opin Drug Saf, 2016,15（11）:1459⁃1462. DOI: 10.1080/14740338.2016.1226279.
［102］	Chiricozzi A, Zangrilli A, Bavetta M, et al. Real⁃life 9⁃year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single⁃centre, retrospective study［J］. J Eur Acad Dermatol Venereol, 2017,31（2）:304⁃311. DOI: 10.1111/jdv. 13771.
［103］	Momose M, Asahina A, Hayashi M, et al. Biologic treatments for elderly patients with psoriasis［J］. J Dermatol, 2017,44（9）:1020⁃1023. DOI: 10.1111/1346⁃8138.13853.
［104］	Mataix J, García L, Belinchón I, et al. Moderate to severe psoriasis in older adults: recommendations on management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology （AEDV）［J］. Actas Dermosifiliogr, 2023,114（9）:802⁃811. DOI: 10.1016/j.ad.2023.07.016.
［105］	Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules［J］. Expert Opin Biol Ther, 2022,22（12）:1503⁃1520. DOI: 10.1080/14712598.2022. 2089020.
［106］	Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate⁃to⁃severe plaque psoriasis: results from the ECLIPSE study［J］. J Dermatolog Treat, 2022,33（4）:2317⁃2324. DOI: 10.1080/09546634.2021.1959504.
［107］	Blauvelt A, Reich K, Spelman L, et al. Consistency of response maintained across demographic subgroups of psoriasis patients treated with guselkumab for up to 3 years in the VOYAGE 1 and 2 trials［J］. J Am Acad Dermatol, 2019, 81（4）: AB38. doi: 10.1016/j.jaad.2019.06.175.
［108］	Laure G, Andreas K, Ferreira Ricardo JO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update［J］. Ann Rheum Dis, 2024,83（6）:706⁃719. DOI: 10.1136/ard⁃2024⁃225531.
［109］	McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis （EXCEED）: a double⁃blind, parallel⁃group, randomised, active⁃controlled, phase 3b trial［J］. Lancet, 2020,395（10235）:1496⁃1505. DOI: 10.1016/S0140⁃6736（20）30564⁃X.
［110］	Walsh JA, Gottlieb AB, Hoepken B, et al. Efficacy of certolizumab pegol with and without concomitant use of disease⁃modifying anti⁃rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID⁃PsA randomized controlled trial［J］. Clin Rheumatol, 2018,37（12）:3285⁃3296. DOI: 10.1007/s10067⁃018⁃4227⁃7.
［111］	Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open⁃label, parallel⁃group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease⁃modifying antirheumatic drug: final results by week 52［J］. Ann Rheum Dis, 2020,79（10）:1310⁃1319. DOI: 10.1136/annrheumdis⁃2020⁃217372.
［112］	Wassenberg S, Rau R, Klopsch T, et al. Etanercept is effective and halts radiographic progression in rheumatoid arthritis and psoriatic arthritis: final results from a German Non⁃interventional Study （PRERA）［J］. Rheumatol Ther, 2023,10（1）:117⁃133. DOI: 10.1007/s40744⁃022⁃00491⁃4.
［113］	Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long⁃term treatment of psoriatic arthritis: a two⁃year followup from a phaseⅢ, randomized, double⁃blind placebo⁃controlled study［J］. Arthritis Care Res （Hoboken）, 2017,69（3）:347⁃355. DOI: 10.1002/acr.23111.
［114］	McInnes IB, Rahman P, Gottlieb AB, et al. Long⁃term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin⁃23, through two years: results from a phaseⅢ, randomized, double⁃blind, placebo⁃controlled study conducted in biologic⁃naive patients with active psoriatic arthritis［J］. Arthritis Rheumatol, 2022,74（3）:475⁃485. DOI: 10.1002/art.42010.
［115］	Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100⁃week results from the phase 3 KEEPsAKE 1 randomized clinical trial［J］. Rheumatol Ther, 2024,11（3）:617⁃632. DOI: 10.1007/s40744⁃024⁃00654⁃5.
［116］	Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100⁃week results from the KEEPsAKE 2 randomized clinical trial［J］. Rheumatol Ther, 2024,11（3）:633⁃648. DOI: 10.1007/s40744⁃024⁃00657⁃2.
［117］	Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post⁃hoc analysis of the phase 3 DISCOVER⁃1 and DISCOVER⁃2 studies［J］. Lancet Rheumatol, 2021,3（10）:e715⁃e723. DOI: 10.1016/S2665⁃9913（21）00105⁃3.
［118］	Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register （BADBIR）［J］. Br J Dermatol, 2020,183（2）:294⁃302. DOI: 10.1111/bjd.18981.
［119］	Yiu Zenas Z N, Gabrielle B, Brian K, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis［J］. JAMA Dermatol, 2022,158（10）:1131⁃1141. DOI: 10.1001/jamadermatol.2022. 2909.
［120］	Gossec L, Siebert S, Bergmans P, et al. Improvement in patient⁃reported outcomes and work productivity following 3⁃year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real⁃world study［J］. Arthritis Res Ther, 2023,25（1）:109. DOI: 10.1186/s13075⁃023⁃03058⁃y.
［121］	Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis［J］. Int J Dermatol, 2016,55（3）:296⁃302. DOI: 10. 1111/ijd.12879.
［122］	Hoffmann JH, Knoop C, Enk AH, et al. Routine laboratory parameter dynamics and laboratory adverse events in psoriasis patients on long⁃term treatment with adalimumab, etanercept, and ustekinumab［J］. Acta Derm Venereol, 2017,97（6）:705⁃710. DOI: 10.2340/00015555⁃2644.
［123］	Zweegers J, van den Reek JMPA, van de Kerkhof PCM, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side⁃effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long⁃term drug⁃survival study from the BioCAPTURE registry［J］. Br J Dermatol, 2016,175（2）:340⁃347. DOI: 10.1111/bjd.14552.
［124］	Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:533⁃541. DOI: 10.1111/jdv.16004.
［125］	Daudén E, de Lima GPG, Armesto S, et al. Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long⁃term experience in Spain［J］. Dermatol Ther （Heidelb）, 2021,11（6）:2207⁃2215. DOI: 10.1007/s13555⁃021⁃00606⁃9.
［126］	Wu C, He C, Wang H, et al. Impact of IL⁃17A inhibitors on serum uric acid levels in psoriatic patients with hyperuricemia: a prospective observational study［J］. Psoriasis （Auckl）, 2024,14:153⁃166. DOI: 10.2147/PTT.S486152.
［127］	Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5⁃year data from reSURFACE 1 and reSURFACE 2［J］. J Eur Acad Dermatol Venereol, 2022,36（10）:1774⁃1783. DOI: 10.1111/jdv.18167.
［128］	Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long⁃term results from 2 phase 3 randomized controlled studies （reSURFACE 1 and reSURFACE 2）［J］. J Am Acad Dermatol, 2021,84（2）:398⁃407. DOI: 10.1016/j.jaad.2020.09.047.
［129］	Ruiz⁃Villaverde R, Rodriguez⁃Fernandez⁃Freire L, Armario⁃Hita JC, et al. Guselkumab: mid⁃term effectiveness, drug survival, and safety in real clinical practice［J］. Dermatol Ther, 2021,34（2）:e14798. DOI: 10.1111/dth.14798.
［130］	Thaçi D, Gerdes S, Du Jardin KG, et al. Efficacy of tildrakizumab across different body weights in moderate⁃to⁃severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies［J］. Dermatol Ther （Heidelb）, 2022,12（10）:2325⁃2341. DOI: 10.1007/s13555⁃022⁃00793⁃z.
［131］	Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials （ReSURFACE 1 and ReSURFACE 2）［J］. J Drugs Dermatol, 2020,19（8）:703⁃708. DOI: 10.36849/JDD.2020.5337.
［132］	Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice［J］. J Dermatolog Treat, 2005,16（5⁃6）:319⁃323. DOI: 10.1080/0954 6630500335977.
［133］	Armstrong Ehrin J, Harskamp Caitlin T, Armstrong April W. Psoriasis and major adverse cardiovascular events: a systematic review and meta⁃analysis of observational studies［J］. J Am Heart Assoc, 2013,2（2）:e000062. DOI: 10.1161/JAHA.113. 000062.
［134］	Rastogi A, Sudhayakumar A, Schaper NC, et al. A paradigm shift for cardiovascular outcome evaluation in diabetes: major adverse cardiovascular events （MACE） to major adverse vascular events （MAVE）［J］. Diabetes Metab Syndr, 2023,17（11）:102875. DOI: 10.1016/j.dsx.2023.102875.
［135］	Wu JJ, Guérin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor⁃α inhibitors versus methotrexate［J］. J Am Acad Dermatol, 2017,76（1）:81⁃90. DOI: 10.1016/j.jaad.2016.07.042.
［136］	Dey AK, Joshi AA, Chaturvedi A, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case⁃cohort study using positron emission tomography/computed tomography［J］. JAMA Cardiol, 2017,2（9）:1013⁃1018. DOI: 10.1001/jamacardio.2017.1213.
［137］	Tablazon ILD, Al⁃Dabagh A, Davis SA, et al. Risk of cardiovascular disorders in psoriasis patients: current and future［J］. Am J Clin Dermatol, 2013,14（1）:1⁃7. DOI: 10.1007/s40257⁃012⁃0005⁃5.
［138］	Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. DOI: 10.1016/j.jaad.2018.11.058.
［139］	de Brito M, Yiu ZZN. Cardiovascular safety of biologics targeting interleukin （IL）⁃12 and/or IL⁃23: what does the evidence say?［J］. Am J Clin Dermatol, 2021,22（5）:587⁃601. DOI: 10.1007/s40257⁃021⁃00612⁃9.
［140］	Stebut Ev, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. DOI: 10.1016/j.jid.2018. 10.042.
［141］	Merola JF, McInnes IB, Deodhar AA, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications［J］. Rheumatol Ther, 2022,9（3）:935⁃955. DOI: 10.1007/s40744⁃022⁃00434⁃z.
［142］	Vera AO, Ro C, Adawi W, et al. Interleukin 23 inhibition associates with lower incidence of cardiovascular risk factor type diseases compared with biologic⁃naïve patients with psoriasis: a retrospective cohort study［J］. J Am Acad Dermatol, 2025,92（2）:337⁃340. DOI: 10.1016/j.jaad.2024.09.063.
［143］	Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease［J］. J Eur Acad Dermatol Venereol, 2009,23（5）:561⁃565. DOI: 10.1111/j.1468⁃3083. 2008.03031.x.
［144］	Schnitzler F, Fidder H, Ferrante M, et al. Long⁃term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single⁃centre cohort［J］. Gut, 2009,58（4）:492⁃500. DOI: 10.1136/gut.2008.155812.
［145］	Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long⁃term Crohn's disease recurrence［J］. Clin Gastroenterol Hepatol, 2014,12（9）:1494⁃1502. DOI: 10.1016/j.cgh.2013.12.035.
［146］	Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease［J］. N Engl J Med, 2016,375（20）:1946⁃1960. DOI: 10.1056/NEJMoa 1602773.
［147］	Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis［J］. N Engl J Med, 2019,381（13）:1201⁃1214. DOI: 10.1056/NEJMoa 1900750.
［148］	Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn's disease: an open⁃label extension study［J］. Lancet Gastroenterol Hepatol, 2018,3（10）:671⁃680. DOI: 10.1016/S2468⁃1253（18）30233⁃4.
［149］	Sandborn WJ, D'Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI⁃1 study［J］. Gastroenterology, 2022,162（6）:1650⁃1664. DOI: 10.1053/j.gastro.2022.01.047.
［150］	Bhat S, Choi D. Guselkumab: a new therapeutic option for the treatment of moderately to severely active ulcerative colitis［J］. Ann Pharmacother, 2025,59（9）:862⁃867. DOI: 10.1177/1060 0280241305441.
［151］	Mu X, Fardy J, Reid S, et al. Severe drug⁃associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis［J］. BMC Gastroenterol, 2021,21（1）:361. DOI: 10.1186/s12876⁃021⁃01936⁃w.
［152］	Waljee AK, Higgins PDR, Jensen CB, et al. Anti⁃tumour necrosis factor⁃α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population⁃based cohort study［J］. Lancet Gastroenterol Hepatol, 2020,5（3）:276⁃284. DOI: 10.1016/S2468⁃1253（19）30362⁃0.
［153］	Gupta A, Peyrin⁃Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with immune⁃mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta⁃analysis［J］. Clin Gastroenterol Hepatol, 2024,22（3）:499⁃512. DOI: 10.1016/j.cgh.2023.07.027.
［154］	Bellinato F, Gisondi P, Maurelli M, et al. IL⁃17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review［J］. Dermatol Ther, 2021,34（2）:e14889. DOI: 10.1111/dth.14889.
［155］	Cazaña TG, Monroig JR, Izu R, et al. Real⁃world outcomes in patients with malignancy and moderate⁃to⁃severe psoriasis treated with guselkumab［J］. JAAD Int, 2024,16:66⁃71. DOI: 10.1016/j.jdin.2024.02.019.

[1]	魏瑾闫会文张建中伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026, 59(7): 671-674.
[2]	宇文天翊周子桢田竞宇陈思涵李敏张峰源顾恒陈旭. 角质形成细胞谷氨酰胺酶1/氨代谢轴在中波紫外线诱导的急性损伤和银屑病皮肤炎症中的表达研究[J]. 中华皮肤科杂志, 2026, 59(7): 654-661.
[3]	李巍姚煦. 中国特应性皮炎的研究现状与展望[J]. 中华皮肤科杂志, 2026, 59(6): 505-511.
[4]	中国“一带一路”皮肤病学专科联盟水疱病专病联盟中华医学会皮肤性病学分会天疱疮/大疱性类天疱疮研究协作组. 抗p200类天疱疮诊断与治疗专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 387-395.
[5]	中国妇幼保健协会儿童变态反应专业委员会儿童皮肤病学组. 儿童肛门生殖器硬化性苔藓诊疗管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 396-406.
[6]	陈廷南梁景耀邓仕琳舒芝荣张锡宝. 生物制剂治疗银屑病与特应性皮炎后出现免疫漂移：临床特征、机制与治疗策略[J]. 中华皮肤科杂志, 2026, 59(5): 474-481.
[7]	张笑旭罗素菊. 乌帕替尼治疗6例掌跖脓疱病的临床疗效与安全性分析[J]. 中华皮肤科杂志, 2026, 59(5): 459-463.
[8]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹病例系列研究[J]. 中华皮肤科杂志, 2026, 59(5): 464-467.
[9]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤病学分会. [开放获取] 肠道菌群移植治疗银屑病专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 427-435.
[10]	中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病专业委员会 . [开放获取] 老年银屑病诊疗与康复专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 407-418.
[11]	中国康复医学会皮肤病康复专业委员会毛发疾病康复学组北京整合医学学会毛发医学分会中华医学会皮肤性病学分会毛发学组国家皮肤与免疫疾病临床医学研究中心. 毛发活检病理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(5): 419-426.
[12]	张翼铭杨卫琴蔡云鹏倪黔键陈健忠张青松. 降压药物与中老年人湿疹患者相关性的病例对照研究[J]. 中华皮肤科杂志, 2026, 59(4): 349-352.
[13]	中国整形美容协会皮肤美容分会中国非公立医疗机构协会皮肤专业委员会. [开放获取] 医用重组人源化胶原蛋白在面部年轻化中的应用专家建议（2026版）[J]. 中华皮肤科杂志, 2026, 59(4): 320-326.
[14]	中华医学会皮肤性病学分会儿童学组中国康复医学会皮肤病康复专业委员会儿童皮肤病学组中国医师协会皮肤科医师分会儿童皮肤病学组中国中药协会儿童健康与药物研究专业委员会外治疗法学组中国医师协会儿科分会皮肤病学组 . 中国儿童斑秃诊断和治疗专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(4): 291-303.
[15]	中国医学装备协会皮肤病与皮肤美容分会中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(4): 304-319.

[开放获取] 斑块状银屑病生物制剂长程治疗管理专家共识（2026版）

Expert consensus on the long-term management of plaque psoriasis with biologic agents （2026 edition）

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 155

相关文章 15

Metrics

本文评价

推荐阅读 10